A few billion dollars paid over several years in the grand scheme of Bristol-Myers Squibb Co.'s massive immuno-oncology portfolio isn't such a huge thing, but more than $2bn in potential milestone fees is a big deal for the recent startup IFM Therapeutics and its investors – and it shows the importance of being able to inflame a tumor with T cells, otherwise known as turning a "cold" tumor "hot."
Nothing about the acquisition of IFM is small, including the $300m upfront fee that Bristol is paying to buy the...








